Frank Gentile - Tekla Healthcare Senior Manager
HQH Stock | USD 16.13 0.01 0.06% |
Executive
Frank Gentile is Senior Manager of Tekla Healthcare Investors
Age | 62 |
Address | 1900 Market Street, Philadelphia, PA, United States, 19103 |
Phone | 215 405 5700 |
Web | https://www.teklacap.com/hqh.html |
Tekla Healthcare Management Efficiency
The current Return On Tangible Assets is estimated to decrease to 0.04. The current Return On Capital Employed is estimated to decrease to 0.04. The Tekla Healthcare's current Total Current Assets is estimated to increase to about 8.3 M, while Total Assets are projected to decrease to under 673 M. Tekla Healthcare's management efficiency ratios could be used to measure how well Tekla Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 6 records | EXECUTIVE Age | ||
Hikmat Hojeibane | Stevia Nutra Corp | N/A | |
Hilary Rodrigues | Stevia Nutra Corp | 80 | |
Brad Long | Stevia Nutra Corp | N/A | |
Ahmed Sheikh | Stevia Nutra Corp | 51 | |
Rene Spaargaren | Stevia Nutra Corp | N/A | |
Robert Dicks | Stevia Nutra Corp | 60 |
Management Performance
Return On Equity | 0.061 | |||
Return On Asset | -8.0E-4 |
Tekla Healthcare Inv Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Bonney, Independent Trustee | ||
Christopher MBA, Senior Manager | ||
Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
Dr MS, Portfolio Manager | ||
Lucinda Stebbins, Independent Trustee | ||
Jeffrey Bailey, Independent Trustee | ||
Daniel Omstead, CEO and President Trustee, Member of Valuation Committee, CEO of Hambrecht and Quist Capital Management LLC and President - HQL and President of Hambrecht and Quist Capital Management LLC and Trustee of HQL | ||
Rakesh Jain, Independent Trustee | ||
MBA MD, VP Mang | ||
Frank Gentile, Senior Manager | ||
Thomas Kent, Independent Trustee | ||
William Reardon, Independent Trustee | ||
Elizabeth Nabel, Independent Trustee | ||
Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
Uwe Reinhardt, Independent Trustee |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.061 | |||
Return On Asset | -8.0E-4 | |||
Profit Margin | 5.47 % | |||
Operating Margin | (0.22) % | |||
Current Valuation | 797.5 M | |||
Shares Outstanding | 50.62 M | |||
Shares Owned By Institutions | 28.27 % | |||
Number Of Shares Shorted | 14.57 K | |||
Price To Earning | 3.38 X | |||
Price To Book | 0.85 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Tekla Stock analysis
When running Tekla Healthcare's price analysis, check to measure Tekla Healthcare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tekla Healthcare is operating at the current time. Most of Tekla Healthcare's value examination focuses on studying past and present price action to predict the probability of Tekla Healthcare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tekla Healthcare's price. Additionally, you may evaluate how the addition of Tekla Healthcare to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Tekla Healthcare's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 1.61 | Earnings Share 1.09 | Revenue Per Share 0.208 | Quarterly Revenue Growth 0.081 |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.